Cargando…

Integrative multiomics-histopathology analysis for breast cancer classification

Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping breast cancers. However, the connections between histology and multi-omics status have never been systematically explored or interpreted. We developed weakly supervised deep learning models over hematoxylin-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ektefaie, Yasha, Yuan, William, Dillon, Deborah A., Lin, Nancy U., Golden, Jeffrey A., Kohane, Isaac S., Yu, Kun-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630188/
https://www.ncbi.nlm.nih.gov/pubmed/34845230
http://dx.doi.org/10.1038/s41523-021-00357-y
_version_ 1784607345587781632
author Ektefaie, Yasha
Yuan, William
Dillon, Deborah A.
Lin, Nancy U.
Golden, Jeffrey A.
Kohane, Isaac S.
Yu, Kun-Hsing
author_facet Ektefaie, Yasha
Yuan, William
Dillon, Deborah A.
Lin, Nancy U.
Golden, Jeffrey A.
Kohane, Isaac S.
Yu, Kun-Hsing
author_sort Ektefaie, Yasha
collection PubMed
description Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping breast cancers. However, the connections between histology and multi-omics status have never been systematically explored or interpreted. We developed weakly supervised deep learning models over hematoxylin-and-eosin-stained slides to examine the relations between visual morphological signal, clinical subtyping, gene expression, and mutation status in breast cancer. We first designed fully automated models for tumor detection and pathology subtype classification, with the results validated in independent cohorts (area under the receiver operating characteristic curve ≥ 0.950). Using only visual information, our models achieved strong predictive performance in estrogen/progesterone/HER2 receptor status, PAM50 status, and TP53 mutation status. We demonstrated that these models learned lymphocyte-specific morphological signals to identify estrogen receptor status. Examination of the PAM50 cohort revealed a subset of PAM50 genes whose expression reflects cancer morphology. This work demonstrates the utility of deep learning-based image models in both clinical and research regimes, through its ability to uncover connections between visual morphology and genetic statuses.
format Online
Article
Text
id pubmed-8630188
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86301882021-12-01 Integrative multiomics-histopathology analysis for breast cancer classification Ektefaie, Yasha Yuan, William Dillon, Deborah A. Lin, Nancy U. Golden, Jeffrey A. Kohane, Isaac S. Yu, Kun-Hsing NPJ Breast Cancer Article Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping breast cancers. However, the connections between histology and multi-omics status have never been systematically explored or interpreted. We developed weakly supervised deep learning models over hematoxylin-and-eosin-stained slides to examine the relations between visual morphological signal, clinical subtyping, gene expression, and mutation status in breast cancer. We first designed fully automated models for tumor detection and pathology subtype classification, with the results validated in independent cohorts (area under the receiver operating characteristic curve ≥ 0.950). Using only visual information, our models achieved strong predictive performance in estrogen/progesterone/HER2 receptor status, PAM50 status, and TP53 mutation status. We demonstrated that these models learned lymphocyte-specific morphological signals to identify estrogen receptor status. Examination of the PAM50 cohort revealed a subset of PAM50 genes whose expression reflects cancer morphology. This work demonstrates the utility of deep learning-based image models in both clinical and research regimes, through its ability to uncover connections between visual morphology and genetic statuses. Nature Publishing Group UK 2021-11-29 /pmc/articles/PMC8630188/ /pubmed/34845230 http://dx.doi.org/10.1038/s41523-021-00357-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ektefaie, Yasha
Yuan, William
Dillon, Deborah A.
Lin, Nancy U.
Golden, Jeffrey A.
Kohane, Isaac S.
Yu, Kun-Hsing
Integrative multiomics-histopathology analysis for breast cancer classification
title Integrative multiomics-histopathology analysis for breast cancer classification
title_full Integrative multiomics-histopathology analysis for breast cancer classification
title_fullStr Integrative multiomics-histopathology analysis for breast cancer classification
title_full_unstemmed Integrative multiomics-histopathology analysis for breast cancer classification
title_short Integrative multiomics-histopathology analysis for breast cancer classification
title_sort integrative multiomics-histopathology analysis for breast cancer classification
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630188/
https://www.ncbi.nlm.nih.gov/pubmed/34845230
http://dx.doi.org/10.1038/s41523-021-00357-y
work_keys_str_mv AT ektefaieyasha integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT yuanwilliam integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT dillondeboraha integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT linnancyu integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT goldenjeffreya integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT kohaneisaacs integrativemultiomicshistopathologyanalysisforbreastcancerclassification
AT yukunhsing integrativemultiomicshistopathologyanalysisforbreastcancerclassification